10-11-2021 05:35 PM | Source: Angel One Ltd
Quote on Alembic Pharmaceuticals receive EIR from USFDA by Mr. Yash Gupta, Angel One Ltd
Below is quote on Alembic Pharmaceuticals receive EIR from USFDA by Mr. Yash Gupta, Equity Research Analyst, Angel One Ltd
Alembic Pharmaceuticals receives EIR for its New Injectable Facility from USFDA.
Alembic Pharmaceuticals Limited receives Establishment Inspection Report (EIR) for its New Injectable Facility (F-3) at Karakhadi from USFDA ( US Food & Drug Administration). USFDA has done an inspection at new injectable factory earlier this year and after the responses submitted by alembic pharmaceuticals, USFDA has issued an EIR for the injectable facility. USFDA also indicated that in the next review cycle they will do the compliance verification.
Above views are of the author and not of the website kindly read disclaimer
Latest News
JSW Cement to invest around Rs 3,000 crore to establ...
GCCA India re-elects Chair and Co-chair for 2024- 2026
Kotak Mahindra Asset Management Company Limited laun...
Evening Roundup : A Daily Report on Bullion Energy &...
JK Tyre records highest ever revenues and profits in...
CapitaLand Investment appoints Sumit Gera as Chief ...
Bajaj Allianz Life Records Profit After Tax of Rs 56...
HCLTech recognized as a Leader in Gartner Magic Quad...
Gold Looks Resisted at Higher Levels, Awaiting Fresh...
Buy SILVER ABOVE 94500 SL BELOW 93700 TGT 95500/9600...
Tag News
India's MedPlus Health posts two-fold surge in Q4 profit on strong sales
Alembic Pharmaceuticals surges on getting EIR for Solid Oral Formulation Facility at Vadodara
Alembic Pharmaceuticals gains on completing ANVISA GMP audit at API-III Facility without any observations
Alembic Pharmaceuticals trades higher on completing USFDA`s inspection at Derma Facility without any observations